Once Health Canada has approved a drug for use in Canada, the country’s public drug plans must decide if the drug will be eligible for public reimbursement. The CADTH Common Drug Review (CDR) plays an important role in their decision-making processes.
The main criterion in the assessment of an examination or treatment method is the benefit for the patients. Does the intervention prolong life or reduce symptoms? Does it improve the quality of life of the patient? To answer these questions, we regularly ask affected patients about their perspective.
Clinical guidelines recommend how healthcare professionals should care for people with specific conditions. They can cover any aspect of a condition and may include recommendations about providing information and advice, prevention, diagnosis, treatment and longer-term management. These guidelines are also important for health service managers and commissioners of NHS services.
The Institute regularly reviews its processes and methodology. This document updates the ‘Guide to the methods of technology appraisal’ published in 2008. This document does not provide a detailed description of the processes used to develop guidance.
Whilst submissions to the PBAC will now need to follow the guidance provided in the PBAC Guidelines version 5.0, the PBAC has approved a transitional arrangement of two PBAC cycles in regard to the structure of submissions.
Anyone – a patient, a health professional, or a pharmaceutical supplier – can make a funding application to PHARMAC. Most applications are provided by pharmaceutical companies, who have access to the full range of information PHARMAC requires to assess applications.
Providing advice about the status of all newly licensed medicines